Analysis of esmolol in human blood by high-performance liquid chromatography and its application to pharmacokinetic studies

Achari, Ramanuj; Drissel, Debra; Thomas, David A.; Shin, Ki Hun; Look, Zee M.

doi:10.1016/s0378-4347(00)81124-x

Cited by 13 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whole blood obtained from the blood bank appeared to have diminished activity compared with fresh blood. In addition, we found that when using the previously described HPLC-UV method [3], specimens from a subset of volunteers contained a UV chromatographic peak, distinguishable with diode array detection, that co-eluted with the carboxylic acid metabolite of esmolol (data not shown). Thus, it is possible that presence of this peak may have been interpreted as evidence of significant esmolol instability by investigators.…”

Section: Discussionmentioning

confidence: 92%

“…As anticipated, the LOQ with this LC-MS was lower than assays that utilized UV detection methods [3,4,6,7], or gas chromatography methods [8]. Most importantly, the sample volume required for this assay was significantly smaller than all previously reported methods, and will allow for multiple sampling in infants and children.…”

Section: Discussionmentioning

confidence: 94%

“…Quon and Stamfli initially reported that NaF was an effective inhibitor of esmolol esterase [2]. Numerous other investigators then used NaF as an inhibitor when studying the pharmacokinetics of esmolol [3,4,[9][10][11]. In 1991 Fan and Zhao reported that NaF concentrations as high as 30 mg/ml were unable to inhibit ex vivo metabolism, but detailed data were not presented [6].…”

Section: Discussionmentioning

confidence: 99%

“…Esmolol is inherently unstable in whole blood due to the ubiquitous presence of red cell esterases [2]. Most previous studies of esmolol pharmacokinetics have utilized sodium fluoride (NaF) to inactivate the red cell esterases [3][4][5]. However, a recent report suggested that NaF in concentrations as high as 30 mg/ml were not effective in stabilizing esmolol in whole blood specimens [6], raising significant concerns about the reliability of previously published results.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Liquid chromatography–electrospray mass spectrometry (LC–MS) method for determination of esmolol concentration in human plasma

Zuppa

Shi

Adamson

2003

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Liquid chromatography–electrospray mass spectrometry (LC–MS) method for determination of esmolol concentration in human plasma

Zuppa

Shi

Adamson

2003

Journal of Chromatography B

View full text Add to dashboard Cite

“…For analysing levobunolol and its metabolite, blood enzymes are inhibited by adding acetonitrile and by freezing the sample (Hengy and Kolle, 1985). The instability of esmolol (Achari et al, 1988) or flestolol (Moore et al, 1986) in blood samples was overcome by collecting these in tubes containing the esterase inhibitor NaF. The sensitivity of hydroxylated propranolol to further oxidation during collection, storage and processing of body fluids is prevented by using an antioxidant, e.g., sodium metabisulfite, sodium bisulfite, vitamin E acetate or ascorbic acid.…”

Section: Body Fluid Collectionmentioning

confidence: 99%

High‐performance liquid chromatographic determination of β‐adrenoceptor blocking agents in body fluids

Šoltés

1989

Biomedical Chromatography

View full text Add to dashboard Cite

Several reports have been published reviewing high-performance liquid chromatographic (HPLC) methods for the determination of beta-adrenoceptor blocking agents (beta-blockers) in biological materials (Flouvat et al., 1981; Mehta, 1983; Marko and Soltés, 1984; Ahnoff et al., 1985; Tkaczyková and Safarík, 1987). Of these, the paper by Mehta (1983) briefly summarizes the interrelationship between physiocochemical properties of beta-blockers with prechromatographic treatment of biological samples, as well as with the HPLC methods used for the determination of 12 beta-adrenoceptor blocking drugs. The work by Ahnoff et al. (1985) concerning the monitoring of cardiovascular drugs also deals with HPLC assays of 18 beta-blockers in plasma. The Appendix to this report presents the great majority of HPLC methods for determining 30 beta-blockers in various body fluids. HPLC methods providing resolution and determination of individual beta-blocker enantiomers have not been included since this topic is being covered by Walle and Walle (1989). The Appendix is just a guide to the methods reviewed for the HPLC determination of parent beta-blockers as well as some of their metabolites co-assayed in various body fluids. It does not include details such as the internal standard, recovery, setting of the detector, limit of determination, etc., given in the individual methods listed. The isolation technique of the drug(s) from the given body fluid represents the main step in the sample work-up procedure. Along with this information, only the type of the HPLC column packing and the detection principle used by each method's developers are given.

show abstract

Development of a Surfactant/Platinum Composite for Sensitive Cardio‐selective Beta Blocker Detection and their Theoretical Studies

et al. 2019

View full text Add to dashboard Cite

An electrooxidative behavior of beta‐blocker drug esmolol was thoroughly investigated by using glassy carbon electrode modified with sodium dodecyl sulfate‐based platinum nanoparticles. The designed nanosensor exhibited remarkable electro‐catalytic effect by dramatically boosting the signal of the esmolol as compared to the bare electrode with detection limit up to picomolar. The effects of pH, scan rate, temperature, deposition potential, deposition time, effect of electrolyte and interfering agents were investigated to optimize conditions for getting intense signal of the analyte. Under optimized experimental conditions, a linear calibration plot for esmolol with a detection limit of 60 pM was obtained. The analyte sensing ability of the modified electrode was supported by the application of theoretical studies that showed favorable interaction between sodium dodecyl sulfate/platinum nanoparticles composite and esmolol. In this study, our aim was to developed a nanosensor for the sensitive detection of esmolol by electrochemical assay. We tried a lot of different modification style and modifiers for creating a sensitive nanosensor for esmolol. This nanosensor can be applied to the esmolol in serum sample without using any further separation, evaporation or precipitation steps. Application could apply in serum sample to test accuracy of our sensor and method. The high recovery results were observed in serum study.

show abstract

Analysis of esmolol in human blood by high-performance liquid chromatography and its application to pharmacokinetic studies

Cited by 13 publications

References 7 publications

Liquid chromatography–electrospray mass spectrometry (LC–MS) method for determination of esmolol concentration in human plasma

Liquid chromatography–electrospray mass spectrometry (LC–MS) method for determination of esmolol concentration in human plasma

High‐performance liquid chromatographic determination of β‐adrenoceptor blocking agents in body fluids

Development of a Surfactant/Platinum Composite for Sensitive Cardio‐selective Beta Blocker Detection and their Theoretical Studies

Contact Info

Product

Resources

About